Uppsala, Sweden and Pickering, Canada,? -??Klaria AB (Klaria) (owned by the parent company Klaria Pharma Holding AB, Stockholm OMX Nasdaq: KLAR) and Purdue Pharma (Canada) today announce that the companies signed an exclusive development agreement for KL -01401 (oromucosal adrenaline film).?KL-01401 is an adrenaline formulation under development for acute treatment of severe allergic reactions in patients with an increased risk of anaphylactic shock.?KL-01401 will be developed jointly by Klaria and Purdue Pharma (Canada).?The development agreement includes exclusive global license and the opportunity to obtain access to the license for the companies that are part of the independent, related Purdue / Napp / Mundipharma network if the project achieves predefined sub-objectives. The total value of Klaria of all sub-objectives defined in the agreement is 55.2 million US dollars.?In addition, Klaria will receive medium to high single digit percentages based on net sales.?The agreement also gives Klaria the exclusive right to manufacture and supply KL-01401 to the global market. As a prerequisite for the agreement with Purdue, Klaria AB has also added adrenaline (epinephrine) to its license agreement with Uppsalagruppen Medical AB.?In this agreement, the Uppsala Group will receive four percent royalties on Klarias net income from the sale of KL-01401. KL-01401 is based on Klaria's unique patented drug delivery platform, which offers most benefits to patients who may need emergency treatment in the event of acute allergic reaction.?It is planned to be offered in the form of an injection-free treatment that is easy to use and allows patients and their caregivers to always carry a life-saving emergency treatment in a discreet manner. - It is very satisfying and inspiring to sign this agreement with Purdue, which is our second cooperation so far.?The agreement combines the strength of our patented drug delivery platform with a partner who is a leader in the development and commercialization of innovative treatments.?We are convinced that the result of our collaboration will meet a medical need without a satisfactory solution today for patients who rely on adrenaline if they were to suffer a serious allergic reaction, says Klari's CEO, Dr. Scott Boyer. - Today's agreement is an exciting step for Purdue with the aim of creating a paradigm shift in the treatment of Canadians who are living with a constant risk of suffering an anaphylactic reaction.?Anaphylactic shock is the most serious type of allergic reaction, and current treatment options continue to face increasing challenges, including its availability.?This deepening of our collaboration with Klaria in the form of a second development agreement is another example of our investments in investment in new technologies and treatment options that are expected to have a positive impact on the healthcare system and patients' lives.?The agreement is fully in line with our overall strategy of expanding our opportunities through business development, says David Pidduck, CEO of Purdue Pharma (Canada). Klaria AB has also added adrenaline (epinephrine) in the company's license agreement with Uppsalagruppen Medical AB.?This agreement means that the Uppsala Group will receive a royalty of four per cent of Klarias net income from the sale of KL-01401. About Klaria AB Klaria develops innovative products with clear medical benefits for patients in need of fast-acting and reliable treatment.?Klaria's products are based on a patented drug delivery film that is combined with clinically tested and established active drug substances.?Klaria is listed on Nasdaq First North under the short name READY.?FNCA Sweden??(?info@fnca.se?, 08-528 00 399)??is the company's Certified Advisor.?More information is available at??www.klaria.com?. About Purdue Pharma (Canada) Purdue Pharma (Canada) is a research-based pharmaceutical and consumer healthcare company that has been operating in Canada for over 60 years.?Its employees have a strong focus on improving Canadians' health and quality of life.?The company has a broad portfolio of prescription and non-prescription drugs including: prescription treatments for pain, ADHD, chemotherapy-related nausea and vomiting (CINV), various ophthalmic indications, and products sold over the counter.?The company contributes to research-based training for the safe use of its products.?The head office in Pickering, Ontario, Canada also includes integrated research and development, wording, and production operations.?Purdue Pharma (Canada) is a privately owned company founded by doctors,?and it is independently linked to the global Purdue / Napp / Mundipharma network.?Read more at?www.purdue.ca For more information, please contact:? Klaria Scott Boyer, CEO Klaria Pharma Holding AB (publ)?scott.boyer@klaria.com?Tel: 08-446 42 99 / 0730-71 64 62?www.?klaria.com Purdue Pharma (Canada) Lisa Joyce, Head of Communications Purdue Pharma (Canada) Pickering, ON, Canada media@purdue.ca This information is such information that Klaria Pharma Holding AB is obliged to publish in accordance with the EU Market Abuse Regulation. ?The information was submitted through the above contact person's agency for publication on January 22, 2019 at.?14.30 CET.